Clinical Trial Detail

NCT ID NCT02358031
Title A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications

oral squamous cell carcinoma

hypopharynx cancer

head and neck squamous cell carcinoma

laryngeal squamous cell carcinoma

oropharynx cancer

nasopharynx carcinoma

Therapies

Cetuximab

Pembrolizumab

Fluorouracil

Carboplatin

Cisplatin

Age Groups: adult

No variant requirements are available.